SlideShare una empresa de Scribd logo
1 de 40
Descargar para leer sin conexión
Reali&es	
  of	
  Addic&on	
  
Dr.	
  Nora	
  Volkow	
  
April	
  2	
  –	
  4,	
  2013	
  
Omni	
  Orlando	
  Resort	
  	
  
at	
  ChampionsGate	
  
Learning	
  Objec&ves	
  
1.	
  Iden=fy	
  recent	
  increasing	
  trends	
  in	
  the	
  misuse	
  
and	
  abuse	
  of	
  prescrip=on	
  drugs.	
  
2.	
  Describe	
  the	
  ways	
  in	
  which	
  the	
  most	
  
commonly	
  abused	
  prescrip=on	
  drug	
  classes	
  
affect	
  the	
  brain	
  and	
  body.	
  
3.	
  Explain	
  strategies	
  being	
  developed	
  and	
  
implemented	
  that	
  will	
  increase	
  awareness	
  of	
  
the	
  growing	
  problem	
  of	
  addic=on.	
  
Disclosure	
  Statement	
  
•  Dr.	
  Nora	
  Volkow	
  has	
  no	
  financial	
  rela=onships	
  
with	
  proprietary	
  en==es	
  that	
  produce	
  health	
  
care	
  goods	
  and	
  services.	
  
Nora D. Volkow, M.D.
Director
Numbers in Millions
 Prescrip&on	
  Drug	
  Misuse/Abuse	
  is	
  a	
  Major	
  Problem	
  in	
  the	
  US	
  
Current	
  Drug	
  Use	
  Rates	
  in	
  Persons	
  Ages	
  12+	
  
Source:	
  	
  SAMHSA,	
  2011	
  Na2onal	
  Survey	
  on	
  Drug	
  Use	
  and	
  Health`	
  
Prevalence of Past Year Drug Use Among 12th graders
2012 Monitoring the Future Study
* Nonmedical use
Drug	
   Prev.	
   Drug	
   Prev.	
  
Tranquilizers*	
  	
  	
   5.3	
  
Marijuana/Hashish	
   36.4	
   Hallucinogens	
   4.8	
  
Small	
  Cigars	
   19.9	
   Seda&ves*	
  	
   4.5	
  
Hookah	
   18.3	
   Salvia	
  	
   4.4	
  
Synthe=c	
  Marijuana	
   11.3	
   OxyCon&n*	
  	
   4.3	
  
Snus	
   7.9	
   Hall	
  other	
  than	
  LSD	
   4.0	
  
Narco2cs	
  o/t	
  
Heroin*	
   7.9	
   MDMA	
  (Ecstasy)	
  	
   3.8	
  
Amphetamines*	
   7.9	
   Inhalants	
  	
   2.9	
  
Adderall*	
  	
   7.6	
   Cocaine	
  (any	
  form)	
  	
   2.7	
  
Vicodin*	
   7.5	
   Ritalin*	
  	
   2.6	
  
Cough	
  Medicine*	
  	
   5.6	
   LSD	
   2.4	
  
Categories not mutually exclusive
0
100
200
300
400
500
600
700
800
900
1000
1100
0 1 2 3 4 5 hr
Time After Amphetamine
%ofBasalRelease
AMPHETAMINE
0
50
100
150
200
0 60 120 180
Time (min)
%ofBasalRelease
Empty
Box Feeding
Di Chiara et al.
FOOD
VTA/SN
nucleus
accumbens
frontal
cortex
These prescription drugs,
like other drugs of abuse
(cocaine, heroin, marijuana)
raise brain dopamine levels
Dopamine	

Neurotransmission	

Why Do People Abuse Prescription Drugs?
Opioids: Examples: OxyContin, Vicodin
Attach to opioid receptors in the
brain and spinal cord, blocking
the transmission of pain messages
and causing an increase in the
activity of dopamine
How They Work…
•  Postsurgical pain relief
•  Management of acute or chronic
pain
•  Relief of coughs and diarrhea
Opioids are Generally Prescribed for:
Amydala
(reward)
NAc
(reward)
Thalamus
(pain)
Similari&es	
  Between	
  Illicit	
  and	
  Prescrip&on	
  Drugs	
  
Stimulants
Enhance brain activity by increasing the activity of
brain excitatory chemical messengers, such as
norepinephrine and dopamine, leading to mental
stimulation
Example: Ritalin
How They Work…
•  ADHD
•  Narcolepsy
•  Depression that does not
respond to other treatments
•  Asthma that does not
respond to other treatment
Stimulants Are Generally Prescribed For:
Methamphetami
ne
Adderall
Similari&es	
  Between	
  Illicit	
  and	
  Prescrip&on	
  Drugs	
  
•  Expectation of Drug Effects
Expectation of clinical benefits vs euphoria high
•  Context of Administration
School, clinic, home vs bar, discotheque
•  Dose and Frequency of Dosing
Lower, fixed regimes vs higher, escalating use
•  Route of Administration
Oral vs injection, smoking, snorting
What is the Difference Between
Therapeutic Use and Abuse?
"High"	
   "High"	
  
0
20
40
60
80
100
0
20
40
60
80
100
0 10 20 30 40 50 60 70 80
%Peak
[11C]Cocaine
Time (min)
[11C]Methylphenidate
0 10 20 30 40 50 60 70 80
Rewarding Effects Depend on How Fast
the Drug Gets into the Brain
0
0.01
0.02
0.03
0.04
0.05
0.06
0 20 40 60 80 100 120
UptakeinStriatum(%/cc)
Time (minutes)
0
0.01
0.02
0.03
0.04
0.05
0.06
UptakeinStriatum(%/cc)
0
0.0005
0.001
0.0015
0.002
0.0025
0.003
0.0035
0 20 40 60 80 100 120
UptakeinStriatum(nCi/cc)
Time (minutes)
iv cocaine iv Ritalin oral Ritalin
Rate of Drug Uptake Into the Brain
Cocaine (iv) and Ritalin (iv) produce a high
but Ritalin (oral) does not.
The slow brain uptake of oral Ritalin
permits effective treatment without a high.
0 20 40 60 80 100 120
Time (minutes)
Fast!!!Fast!!! Slow!!!
Source:	
  Volkow,	
  ND	
  et	
  al.,	
  Journal	
  of	
  Neuroscience,	
  23,	
  pp.	
  11461-­‐11468,	
  December	
  2003.	
  
Glucose	
  Metabolism	
  Was	
  Greatly	
  Increased	
  
By	
  the	
  Expecta2on	
  of	
  the	
  Drug	
  	
  	
  
Unexpected MP70
0
µmol/100g/min
Expected MP
Increases	
  in	
  Metabolism	
  Were	
  About	
  50%	
  
Larger	
  When	
  MP	
  Was	
  Expected	
  Than	
  
Unexpected	
  
0
5
10
15
20
25
30
%Change
Unexpected	
  
MP	
  
Expected	
  
MP	
  
Expected	
  MP	
  
Got	
  Placebo	
  
What	
  Has	
  Raised	
  Our	
  AUen2on	
  to	
  the	
  	
  
Problem	
  of	
  Prescrip2on	
  Drug	
  Abuse?	
  	
  
Source: SAMHSA Treatment Episode Data Set
(TEDS), 2000-2010
28,326
37,649
45,882
52,664
60,824
71,048
82,359
98,386
122,185
142,124
157,171
0
20,000
40,000
60,000
80,000
100,000
120,000
140,000
160,000
180,000
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
More Than 5-Fold Increase
In Treatment Admissions For
Prescription Painkillers
In the Past Decade
12	
  
10	
  
8	
  
6	
  
4	
  
2	
  
0	
   1990	
  	
  	
  	
  	
  1992	
  	
  	
  	
  	
  1994	
  	
  	
  	
  	
  1996	
  	
  	
  	
  	
  1998	
  	
  	
  	
  2000	
  	
  	
  	
  	
  2002	
  	
  	
  	
  	
  2004	
  	
  	
  	
  	
  2006	
  	
  	
  	
  	
  2008	
  
*Deaths	
  are	
  those	
  for	
  which	
  poisoning	
  by	
  drugs	
  (illicit,	
  prescrip=on,	
  and	
  	
  over-­‐the-­‐counter)	
  was	
  the	
  underlying	
  cause.
Drug	
  Overdose	
  Death	
  Rates	
  
	
  in	
  the	
  US	
  Have	
  More	
  	
  
Than	
  Tripled	
  since	
  1990	
  
Na&onal	
  Vital	
  Sta&s&cs	
  System.	
  	
  	
  
Drug	
  	
  Overdose	
  Death	
  Rates	
  by	
  State	
  2008.	
  
100	
  people	
  die	
  from	
  drug	
  
overdoses	
  every	
  day	
  in	
  the	
  US	
  
35,00
0
30,00
0
25,00
0
20,00
0
15,00
0
10,00
0
5,000
0
Number	
  of	
  ED	
  Visits	
  
9,000
6,000
3,000
0
Aged	
  5	
  to	
  11	
   Aged	
  12	
  to	
  17	
   Aged	
  18	
  to	
  25	
   Aged	
  26	
  to	
  34	
   Aged	
  35	
  or	
  Older	
  
2005	
  
2010	
  
3,322	
  
3,791	
  
2,702	
  
3,461	
  
2,131	
  
8,148	
  
1,754	
  
6,094	
  
2,519	
  
7,957	
  
Number	
  of	
  ED	
  Visits	
  
2005	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  2006	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  2007	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  2008	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  2009	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  2010	
  
4,315	
  
6,332	
  
11,390	
   11,448	
   12,208	
  
14,068	
  
17,174	
  
14,503	
  
12,287	
  
14,979	
  
10,614	
  
9,059	
  
13,379	
  
16,948	
  
26,369	
  
23,735	
  
26,711	
  
31,244	
  
All	
  
Males	
  
Females	
  
Emergency Department (ED) Visits Related to
Stimulant Medications
Source:	
  SAMHSA	
  Dawn	
  Report:Emergency	
  Department	
  Visits	
  Involving	
  AUen2on	
  Deficit/	
  
Hyperac2vity	
  Disorder	
  S2mulant	
  Medica2ons	
  ,	
  January	
  24,	
  2013.	
  	
  
Data in Several States Show That Hepatitis C Virus
Among Adolescents and Young Adults
Has Increased in Recent Years
Of	
  cases	
  with	
  available	
  risk	
  data,	
  injec2on	
  drug	
  use	
  
(IDU)	
  was	
  the	
  most	
  common	
  risk	
  factor	
  for	
  HCV	
  
transmission	
  	
  
Although	
  only	
  a	
  small	
  number	
  of	
  these	
  
cases	
  responded	
  to	
  further	
  inves2ga2on…..	
  
• 	
  	
  92%	
  reported	
  opioid	
  
	
  	
  	
  analgesic	
  abuse	
  	
  
• 	
  	
  89%	
  reported	
  heroin	
  use	
  
• 	
  	
  95%	
  used	
  opioid	
  analgesics	
  	
  
	
  	
  	
  before	
  switching	
  to	
  heroin	
  
• 	
  	
  During	
  the	
  preceding	
  6	
  months,	
  	
  
	
  	
  	
  the	
  most	
  frequently	
  injected	
  	
  
	
  	
  	
  drugs	
  were	
  heroin	
  (50%)	
  
	
  	
  	
  and	
  opioid	
  analgesics	
  (30%)	
  
CDC, MMWR, May 6, 2011/60(17); 537-541;CDC,	
  MMWR,	
  October	
  28,	
  2011/60(42):1457-­‐1458	
  
Number of Opioid Prescriptions Dispensed by
U.S. Retail Pharmacies, Years 1991-2011
76 78 80
86 91 96 100
109
120
131
139
144
151
158
169
180
192
201 202
210
219
0
50
100
150
200
250
91
92
93
94
95
96
97
98
99
2000
01
02
03
04
05
06
07
08
09
10
11
Prescriptions(millions)
IMS’s Source Prescription Audit (SPA) &
Vector One®: National (VONA)
Opioids Hydrocodone Oxycodone
Oxycodone and Hydrocodone Prescriptions
1998-2012
Codeine & Comb NON-INJ (USC 02232), Morphine & Opium NON-INJ
(USC 0222), Morphine & Opium INJ (USC 02221), Codeine & Comb INJ
(USC 02231).
Source: SDI Health, VONA
16 19 22 25 27 29 31 34 38 43 47 49 54 57 57
72
83
90
96 101 106 110
120
126
132 133 130 131 136 134
0
20
40
60
80
100
120
140
160
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Millions
Oxycodone (Schedule II)
Hydrocodone (Schedule III)
Opioid Prescriptions
by Age
2
6
19
30
159
-
20
40
60
80
100
120
140
160
180
-
5
10
15
20
25
30
35
2002 2006 2009 2012
No.ofPrescriptions,Age40+(millions)
No.ofPrescriptions(millions)
0 to 9 10 to 19 20 to 29
30 to 39 40+
IMS Health, Vector One® National
Opioids Overdose
Death by Age Group,
US, 2008
Rate	
  per	
  100,000	
  
Paulozzi LJ, J Safety Res 2012; 43(4):
283-289.
20%	
  
15%	
  
11%	
  
10%	
  
9%	
  
27%	
  
12%	
  
11%	
  
8%	
  
5%	
  
20%	
  
16%	
  
11%	
  
9%	
  
6%	
  
20%	
  
13%	
  
9%	
  
8%	
  
7%	
  
16%	
  
12%	
  
7%	
  
6%	
  
3%	
  
0	
   0.1	
   0.2	
   0.3	
  
Percentage of Prescriptions Dispensed for Opioid Analgesics from
Outpatient US Retail Pharmacies, by Age Group
20062002
22%	
  
16%	
  
11%	
  
10%	
  
8%	
  
27%	
  
12%	
  
11%	
  
8%	
  
5%	
  
19%	
  
18%	
  
12%	
  
8%	
  
7%	
  
24%	
  
12%	
  
10%	
  
8%	
  
7%	
  
26%	
  
17%	
  
9%	
  
7%	
  
4%	
  
0	
   0.2	
  
0 to 9
10 to 19
20 to
29
30 to 39
≥40
EN Phys
Pediatrici
an
Dentist
Emerg
Med
GP/FM/
DO
Ortho
Surg
OB/GYN
Intern
Med
Anesthes
IMS Health, Vector One®
National
23%	
  
16%	
  
13%	
  
11%	
  
6%	
  
29%	
  
12%	
  
8%	
  
8%	
  
6%	
  
17%	
  
16%	
  
13%	
  
8%	
  
8%	
  
21%	
  
10%	
  
9%	
  
8%	
  
7%	
  
25%	
  
16%	
  
7%	
  
6%	
  
6%	
  
-­‐10%	
   10%	
   30%	
  
2012
Top Prescribers of Opioid Analgesics in
2012
0
10,000,000
20,000,000
30,000,000
40,000,000
50,000,000
60,000,000
20022003200420052006200720082009201020112012
Prescriptions
GP/FM/DO
Internal medicine
Dentistry
Orthopedic
Surgery
IMS Health, Vector One® National
Percent	
  
Source:	
  2010	
  Na2onal	
  Survey	
  on	
  Drug	
  Use	
  and	
  Health,	
  SAMHSA	
  2011.	
  
Source	
  of	
  Prescrip&on	
  Drugs	
  	
  
(how	
  they	
  obtained	
  the	
  drugs	
  they	
  most	
  recently	
  used	
  
nonmedically)	
   Rates	
  averaged	
  across	
  2009	
  and	
  2010	
  
Jones, CM et al. JAMA, February 20, 2013; 309(7): 657-659.
National Center for Health Statistics show drug overdose deaths
increased for the 11th consecutive year in 2010
In	
  2010,	
  there	
  were	
  38,329	
  drug	
  
overdose	
  
deaths	
  in	
  the	
  United	
  States	
  
Percentage	
  of	
  Overdose	
  Deaths	
  for	
  	
  Specific	
  Psychotherapeu=c	
  and	
  
	
  CNS	
  Pharmaceu=cals	
  that	
  Involved	
  a	
  Single	
  Drug	
  Class,	
  US,	
  2010	
  	
  
Psychotherapeuticand
CNSPharmaceuticals,%
Opioid	
  	
  
Analgesics	
  
(n=16,651)	
  
An&epilep&c	
  &	
  
An&parkinsonism	
  
Drugs	
  
(n=1,717)	
  
Benzodizepines	
  
(n=6,497)	
  
Barbiturates	
  
(n=296)	
  
An&depressants	
  
(n=3,889)	
  
An&psycho&c	
  &	
  
Neurolep&c	
  
Drugs	
  
(n=1,351)	
  
	
  Other	
  
Psychotropic	
  
Drugs	
  
(n=24)	
  
35
30
25
20
15
10
5
0
Jones, CM et al. JAMA, February 20, 2013; 309(7): 657-659.
PERCENT
	
  	
  	
  Drug	
  Involvement	
  in	
  Pharmaceu=cal	
  Overdose	
  Deaths	
  	
  
	
  	
  	
  Opioid	
  Analgesic	
  Involvement	
  in	
  Deaths	
  for	
  Specific	
  Drugs	
  
Specific	
  Drug	
  Involvement	
  in	
  Pharmaceu&cal	
  Overdose	
  
Deaths	
  USA,	
  2010	
  
75.2
7.8
29.4
1.3
17.6
6.1
0.1
100
65.5
77.2
50
57.6 58
54.2
0
20
40
60
80
100
120
How to Minimize the Diversion and
Abuse of Prescription Medications
Engage the Healthcare System
Doctors Need to Know…
What Opioid Prescriptions Have Been Given to
Their Patients By Other Doctors or Practitioners
This information should be:
1)  included in the patients’
electronic health care records
2)  accessible through a
Prescription Drug Monitoring
Program (PDMP) that provides
immediate information and can
cross-reference across States
Mezei,	
  L	
  and	
  Murinson,	
  BB.,	
  J	
  Pain,	
  12,	
  1199	
  -­‐1208,	
  2011.	
  
Education on Pain in Medical Schools
Number of Hours of Pain Education
Number	
  of	
  	
  Schools	
  
USA (median: 7 hours)
Canada (median: 14 hours)
Veterinarian schools:
75 hours on pain
0-5 5-10 10-15 15-20 20-25 25-30 >30
•  Centers of Excellence in Pain Education (12 CoEPE)
•  Consensus Workshop on Opioids
for Chronic Pain
ICs Involved:
ORWH NIA
OBSSR NINR
NIDA NICHD
NIDCR NIAMS
NINDS NCCAM
•  Efficacy of opioids for treating chronic pain
•  How to administer opioids for optimal efficacy and minimal
adverse effects
•  Risks for addiction
•  Populations differences
•  What training is available (other than offered by industry) for
teaching how and what type of opioids should be used in
managing chronic pain?
•  What research directions need to be pursued to determine best
approaches for managing chronic pain with opioids?
•  For research gaps, what are research priorities?
Consensus Workshop: Opioids for Chronic Pain
Prevention Strategies – Public Education
CME Courses developed by NIDA & Medscape Education, funded by ONDCP
Safe	
  Prescribing	
  for	
  Pain	
  
Managing	
  Pain	
  Pa&ents	
  	
  
Who	
  Abuse	
  Rx	
  Drugs	
  
Skills	
  and	
  tools	
  clinicians	
  
can	
  use	
  to	
  screen	
  for	
  and	
  
prevent	
  abuse	
  in	
  pa7ents	
  
with	
  pain	
  	
  	
  
Learn	
  symptoms	
  of	
  opioid	
  addic7on	
  
and	
  dependence	
  in	
  pa7ents	
  with	
  
chronic	
  pain,	
  	
  
and	
  how	
  to	
  screen	
  for,	
  prevent	
  	
  	
  	
  
and	
  treat	
  such	
  condi7ons	
  	
  
Pain	
  Medica&ons	
  	
  
•  Develop medications with slower abuse
potential including drugs that don’t cross
BBB (i.e., CBR2 agonist)
•  Develop slow release formulations (low
dose and long duration)
•  Develop novel formulations to
reduce abuse liability including
mixture formulations (e.g., naloxone
and buprenorphine)
0
0.0005
0.001
0.0015
0.002
0.0025
0.003
0.0035
0 20 40 60 80 100120
UptakeinStriatum(nCi/cc)
Time (minutes)
Slow!!!
Prevention Strategies – Overdose Intervention
•  Naloxone Distribution for opioid
overdose victims. The potential for
direct intervention to save lives.
•  Naloxone Nasal Spray Development
Needle-free, unit-dose, ready-to-use
opioid overdose antidote
NIDA	
  STTR	
  Grantee	
  –	
  An7Op,	
  Inc.,	
  Daniel	
  Wermeling,	
  CEO	
  	
  
Contact:	
  E-­‐mail:	
  dpwermeling@gmail.com,	
  Tel:	
  
859-­‐221-­‐4138	
  
Treatment of Addiction to Prescription Opioids
Buprenorphine
Currently	
  19,000	
  physicians	
  
are	
  certified	
  to	
  prescribe	
  buprenorphine	
  
(Source:	
  CSAT	
  Buprenorphine	
  Information	
  Center)	
  
Targets the same opioid receptors as
morphine (mu) but its much less potent,
has a much longer half life and does not
produce the same high as heroin or
morphine
Universal Drug Abuse Prevention
May Reduce Prescription Drug Misuse
Spoth et al., Addiction 2008;103(7):1160-1168.
Spoth, et al., AJPM 2011;40(4):440-447
For 100 young adults
in general population
starting Rx abuse,
only 35 young adults
from an intervention
community started.
Overall, three studies
now suggest the
impact of universal
prevention on
prescription drug
abuse.
www.drugabuse.gov
Numbers	
  in	
  Thousands	
  
Source:	
  2011	
  Na2onal	
  Survey	
  on	
  Drug	
  Use	
  and	
  Health,	
  SAMHSA,	
  2012.	
  
Large Number of Past Year Initiates of Pharmaceuticals:
Persons Aged 12 or Older, 2011
Marijuana
Pain Relievers
Tranquilizers
Ecstasy
Inhalants
Cocaine
Stimulants
LSD
Heroin
Sedatives
PCP
Overdoses of prescription painkillers
have more than tripled in the past 20
years, killing more than 15,500 people in
the US in 2009
For	
  every	
  	
  	
  	
  	
  	
  overdose	
  death	
  
from	
  prescrip=on	
  painkillers	
  	
  
there	
  are	
  
treatment	
  admissions	
  for	
  abuse	
  
emergency	
  	
  department	
  visits	
  
for	
  misuse	
  or	
  abuse	
  
people	
  who	
  abuse	
  
or	
  are	
  dependent	
  
people	
  who	
  take	
  prescrip=on	
  
	
  painkillers	
  for	
  non-­‐medical	
  use	
  
10	
  
32	
  
130	
  
825	
  

Más contenido relacionado

La actualidad más candente

iCAAD London 2019 - Mel Pohl - CHRONIC PAIN AND ADDICTION: HOW WE MISSED THE...
 iCAAD London 2019 - Mel Pohl - CHRONIC PAIN AND ADDICTION: HOW WE MISSED THE... iCAAD London 2019 - Mel Pohl - CHRONIC PAIN AND ADDICTION: HOW WE MISSED THE...
iCAAD London 2019 - Mel Pohl - CHRONIC PAIN AND ADDICTION: HOW WE MISSED THE...iCAADEvents
 
Cannabis, the good, the bad and the ugly
Cannabis, the good, the bad and the uglyCannabis, the good, the bad and the ugly
Cannabis, the good, the bad and the uglyMS Trust
 
Management of High Disease Activity in Multiple Sclerosis (MS)
Management of High Disease Activity in Multiple Sclerosis (MS)Management of High Disease Activity in Multiple Sclerosis (MS)
Management of High Disease Activity in Multiple Sclerosis (MS)Sudhir Kumar
 
$MAPP Phase 3 results
$MAPP Phase 3 results$MAPP Phase 3 results
$MAPP Phase 3 resultsJames Hilbert
 
Prescribing by specialty
Prescribing by specialtyPrescribing by specialty
Prescribing by specialtyPaul Coelho, MD
 
NEDA in multiple sclerosis
NEDA in multiple sclerosisNEDA in multiple sclerosis
NEDA in multiple sclerosisSudhir Kumar
 
Analyzing the neuroprotective potential of nicotine in Parkinson's Disease (P...
Analyzing the neuroprotective potential of nicotine in Parkinson's Disease (P...Analyzing the neuroprotective potential of nicotine in Parkinson's Disease (P...
Analyzing the neuroprotective potential of nicotine in Parkinson's Disease (P...Daniella Lock
 
7 Famous Myths About CBD oil And Marijuana - Hemprove
7 Famous Myths About  CBD oil And Marijuana - Hemprove7 Famous Myths About  CBD oil And Marijuana - Hemprove
7 Famous Myths About CBD oil And Marijuana - HemproveHemprove
 
iCAAD London 2019 - Antonio Metastasio - PERSONALISED MEDICINE IN THE TREATM...
 iCAAD London 2019 - Antonio Metastasio - PERSONALISED MEDICINE IN THE TREATM... iCAAD London 2019 - Antonio Metastasio - PERSONALISED MEDICINE IN THE TREATM...
iCAAD London 2019 - Antonio Metastasio - PERSONALISED MEDICINE IN THE TREATM...iCAADEvents
 
Clinical trials faces 2010
Clinical trials faces 2010Clinical trials faces 2010
Clinical trials faces 2010NYU FACES
 
Rounds june 2016, the last round up
Rounds june  2016, the last round upRounds june  2016, the last round up
Rounds june 2016, the last round upmary jane waite
 
Pregnant women with anxiety and other mood disorders more likely to report us...
Pregnant women with anxiety and other mood disorders more likely to report us...Pregnant women with anxiety and other mood disorders more likely to report us...
Pregnant women with anxiety and other mood disorders more likely to report us...Δρ. Γιώργος K. Κασάπης
 
Methadone Use and Pregnancy
Methadone Use and PregnancyMethadone Use and Pregnancy
Methadone Use and Pregnancymeducationdotnet
 
Chemotherapy Induced Peripheral Neuropathy
Chemotherapy Induced Peripheral NeuropathyChemotherapy Induced Peripheral Neuropathy
Chemotherapy Induced Peripheral NeuropathyEmad Shash
 
Nicholas Jewell MedicReS World Congress 2011
Nicholas Jewell MedicReS World Congress 2011Nicholas Jewell MedicReS World Congress 2011
Nicholas Jewell MedicReS World Congress 2011MedicReS
 

La actualidad más candente (20)

iCAAD London 2019 - Mel Pohl - CHRONIC PAIN AND ADDICTION: HOW WE MISSED THE...
 iCAAD London 2019 - Mel Pohl - CHRONIC PAIN AND ADDICTION: HOW WE MISSED THE... iCAAD London 2019 - Mel Pohl - CHRONIC PAIN AND ADDICTION: HOW WE MISSED THE...
iCAAD London 2019 - Mel Pohl - CHRONIC PAIN AND ADDICTION: HOW WE MISSED THE...
 
Cannabis, the good, the bad and the ugly
Cannabis, the good, the bad and the uglyCannabis, the good, the bad and the ugly
Cannabis, the good, the bad and the ugly
 
Management of High Disease Activity in Multiple Sclerosis (MS)
Management of High Disease Activity in Multiple Sclerosis (MS)Management of High Disease Activity in Multiple Sclerosis (MS)
Management of High Disease Activity in Multiple Sclerosis (MS)
 
$MAPP Phase 3 results
$MAPP Phase 3 results$MAPP Phase 3 results
$MAPP Phase 3 results
 
Wesat2202
Wesat2202Wesat2202
Wesat2202
 
Prescribing by specialty
Prescribing by specialtyPrescribing by specialty
Prescribing by specialty
 
NEDA in multiple sclerosis
NEDA in multiple sclerosisNEDA in multiple sclerosis
NEDA in multiple sclerosis
 
Brivaracetam
BrivaracetamBrivaracetam
Brivaracetam
 
Analyzing the neuroprotective potential of nicotine in Parkinson's Disease (P...
Analyzing the neuroprotective potential of nicotine in Parkinson's Disease (P...Analyzing the neuroprotective potential of nicotine in Parkinson's Disease (P...
Analyzing the neuroprotective potential of nicotine in Parkinson's Disease (P...
 
7 Famous Myths About CBD oil And Marijuana - Hemprove
7 Famous Myths About  CBD oil And Marijuana - Hemprove7 Famous Myths About  CBD oil And Marijuana - Hemprove
7 Famous Myths About CBD oil And Marijuana - Hemprove
 
iCAAD London 2019 - Antonio Metastasio - PERSONALISED MEDICINE IN THE TREATM...
 iCAAD London 2019 - Antonio Metastasio - PERSONALISED MEDICINE IN THE TREATM... iCAAD London 2019 - Antonio Metastasio - PERSONALISED MEDICINE IN THE TREATM...
iCAAD London 2019 - Antonio Metastasio - PERSONALISED MEDICINE IN THE TREATM...
 
Clinical trials faces 2010
Clinical trials faces 2010Clinical trials faces 2010
Clinical trials faces 2010
 
Rounds june 2016, the last round up
Rounds june  2016, the last round upRounds june  2016, the last round up
Rounds june 2016, the last round up
 
Pregnant women with anxiety and other mood disorders more likely to report us...
Pregnant women with anxiety and other mood disorders more likely to report us...Pregnant women with anxiety and other mood disorders more likely to report us...
Pregnant women with anxiety and other mood disorders more likely to report us...
 
MS research 2013
MS research 2013MS research 2013
MS research 2013
 
Diabetes and its complications
Diabetes and its complicationsDiabetes and its complications
Diabetes and its complications
 
WPUPC Poster
WPUPC PosterWPUPC Poster
WPUPC Poster
 
Methadone Use and Pregnancy
Methadone Use and PregnancyMethadone Use and Pregnancy
Methadone Use and Pregnancy
 
Chemotherapy Induced Peripheral Neuropathy
Chemotherapy Induced Peripheral NeuropathyChemotherapy Induced Peripheral Neuropathy
Chemotherapy Induced Peripheral Neuropathy
 
Nicholas Jewell MedicReS World Congress 2011
Nicholas Jewell MedicReS World Congress 2011Nicholas Jewell MedicReS World Congress 2011
Nicholas Jewell MedicReS World Congress 2011
 

Destacado

Building public safety_public_health_partnerships_final
Building public safety_public_health_partnerships_finalBuilding public safety_public_health_partnerships_final
Building public safety_public_health_partnerships_finalOPUNITE
 
Treatment opioids a_comprehensive_response_final
Treatment opioids a_comprehensive_response_finalTreatment opioids a_comprehensive_response_final
Treatment opioids a_comprehensive_response_finalOPUNITE
 
Successful strategies for_community_change_part1_final
Successful strategies for_community_change_part1_finalSuccessful strategies for_community_change_part1_final
Successful strategies for_community_change_part1_finalOPUNITE
 
Trends in rx_drug_abuse_final
Trends in rx_drug_abuse_finalTrends in rx_drug_abuse_final
Trends in rx_drug_abuse_finalOPUNITE
 
Technologies in preventing_diversion-ne_wweb
Technologies in preventing_diversion-ne_wwebTechnologies in preventing_diversion-ne_wweb
Technologies in preventing_diversion-ne_wwebOPUNITE
 
Successful strategies for_community_change_part3_final
Successful strategies for_community_change_part3_finalSuccessful strategies for_community_change_part3_final
Successful strategies for_community_change_part3_finalOPUNITE
 
Treatment options for_juveniles_final
Treatment options for_juveniles_finalTreatment options for_juveniles_final
Treatment options for_juveniles_finalOPUNITE
 
Enabling and intervention_final
Enabling and intervention_finalEnabling and intervention_final
Enabling and intervention_finalOPUNITE
 
Overview of the Public Health Burden of Prescription Drug and Heroin Overdos...
Overview of the Public Health  Burden of Prescription Drug and Heroin Overdos...Overview of the Public Health  Burden of Prescription Drug and Heroin Overdos...
Overview of the Public Health Burden of Prescription Drug and Heroin Overdos...University of Michigan Injury Center
 
Drug abuse ppt
Drug abuse pptDrug abuse ppt
Drug abuse pptDFC2011
 

Destacado (11)

Building public safety_public_health_partnerships_final
Building public safety_public_health_partnerships_finalBuilding public safety_public_health_partnerships_final
Building public safety_public_health_partnerships_final
 
Treatment opioids a_comprehensive_response_final
Treatment opioids a_comprehensive_response_finalTreatment opioids a_comprehensive_response_final
Treatment opioids a_comprehensive_response_final
 
Successful strategies for_community_change_part1_final
Successful strategies for_community_change_part1_finalSuccessful strategies for_community_change_part1_final
Successful strategies for_community_change_part1_final
 
Trends in rx_drug_abuse_final
Trends in rx_drug_abuse_finalTrends in rx_drug_abuse_final
Trends in rx_drug_abuse_final
 
Technologies in preventing_diversion-ne_wweb
Technologies in preventing_diversion-ne_wwebTechnologies in preventing_diversion-ne_wweb
Technologies in preventing_diversion-ne_wweb
 
Successful strategies for_community_change_part3_final
Successful strategies for_community_change_part3_finalSuccessful strategies for_community_change_part3_final
Successful strategies for_community_change_part3_final
 
Treatment options for_juveniles_final
Treatment options for_juveniles_finalTreatment options for_juveniles_final
Treatment options for_juveniles_final
 
Enabling and intervention_final
Enabling and intervention_finalEnabling and intervention_final
Enabling and intervention_final
 
Overview of the Public Health Burden of Prescription Drug and Heroin Overdos...
Overview of the Public Health  Burden of Prescription Drug and Heroin Overdos...Overview of the Public Health  Burden of Prescription Drug and Heroin Overdos...
Overview of the Public Health Burden of Prescription Drug and Heroin Overdos...
 
Amalgam cavity design
Amalgam cavity designAmalgam cavity design
Amalgam cavity design
 
Drug abuse ppt
Drug abuse pptDrug abuse ppt
Drug abuse ppt
 

Similar a Realities of addiction_volkow-final

Tue gs volkow
Tue gs volkowTue gs volkow
Tue gs volkowOPUNITE
 
addiction science.ppt
addiction science.pptaddiction science.ppt
addiction science.pptLeonilEstao
 
Neurobiology of drug abuse and addiction_NIDA
Neurobiology of drug abuse and addiction_NIDANeurobiology of drug abuse and addiction_NIDA
Neurobiology of drug abuse and addiction_NIDAGeorgePanagis3
 
Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...
Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...
Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...University of Michigan Injury Center
 
Rx15 general wed_800_revised4-6_volkow rx drug summit 2015 final ndv3
Rx15 general wed_800_revised4-6_volkow rx drug summit 2015 final ndv3Rx15 general wed_800_revised4-6_volkow rx drug summit 2015 final ndv3
Rx15 general wed_800_revised4-6_volkow rx drug summit 2015 final ndv3OPUNITE
 
Rx15 vision wed_200_ondcp_1_labelle_2jones_3spitznas
Rx15 vision wed_200_ondcp_1_labelle_2jones_3spitznasRx15 vision wed_200_ondcp_1_labelle_2jones_3spitznas
Rx15 vision wed_200_ondcp_1_labelle_2jones_3spitznasOPUNITE
 
12Week IV, Discussion Post Care for the Client with a Subst
12Week IV, Discussion Post Care for the Client with a Subst12Week IV, Discussion Post Care for the Client with a Subst
12Week IV, Discussion Post Care for the Client with a Substlauvicuna8dw
 
12Week IV, Discussion Post Care for the Client with a Subst
12Week IV, Discussion Post Care for the Client with a Subst12Week IV, Discussion Post Care for the Client with a Subst
12Week IV, Discussion Post Care for the Client with a Substdrennanmicah
 
12Week IV, Discussion Post Care for the Client with a Subst.docx
12Week IV, Discussion Post Care for the Client with a Subst.docx12Week IV, Discussion Post Care for the Client with a Subst.docx
12Week IV, Discussion Post Care for the Client with a Subst.docxherminaprocter
 
12Week IV, Discussion Post Care for the Client with a Subst.docx
12Week IV, Discussion Post Care for the Client with a Subst.docx12Week IV, Discussion Post Care for the Client with a Subst.docx
12Week IV, Discussion Post Care for the Client with a Subst.docxRAJU852744
 
Rx16 vs ukhealthcare_800_group
Rx16 vs ukhealthcare_800_groupRx16 vs ukhealthcare_800_group
Rx16 vs ukhealthcare_800_groupOPUNITE
 
আসক্তি মুক্তি Ashokti mukti
আসক্তি মুক্তি Ashokti muktiআসক্তি মুক্তি Ashokti mukti
আসক্তি মুক্তি Ashokti muktiAtiqul Haq Mazumder
 
Rx15 pharma wed_430_1_green_2yamada-dole
Rx15 pharma wed_430_1_green_2yamada-doleRx15 pharma wed_430_1_green_2yamada-dole
Rx15 pharma wed_430_1_green_2yamada-doleOPUNITE
 
Managing Patients on Opioids for Chronic Noncancer Pain
Managing Patients on Opioids for Chronic Noncancer PainManaging Patients on Opioids for Chronic Noncancer Pain
Managing Patients on Opioids for Chronic Noncancer PainAngela Solleder
 
Neonatal Abstinence Syndrome - Tennessee's Epidemic and The State's Response
Neonatal Abstinence Syndrome - Tennessee's Epidemic and The State's ResponseNeonatal Abstinence Syndrome - Tennessee's Epidemic and The State's Response
Neonatal Abstinence Syndrome - Tennessee's Epidemic and The State's ResponseHealth Easy Peasy
 

Similar a Realities of addiction_volkow-final (20)

Tue gs volkow
Tue gs volkowTue gs volkow
Tue gs volkow
 
Brain Science
Brain ScienceBrain Science
Brain Science
 
NORA VOLKOW RX DRUG ABUSE | HEROIN SUMMIT 2016
NORA VOLKOW RX DRUG ABUSE | HEROIN SUMMIT 2016NORA VOLKOW RX DRUG ABUSE | HEROIN SUMMIT 2016
NORA VOLKOW RX DRUG ABUSE | HEROIN SUMMIT 2016
 
addiction science.ppt
addiction science.pptaddiction science.ppt
addiction science.ppt
 
Neurobiology of drug abuse and addiction_NIDA
Neurobiology of drug abuse and addiction_NIDANeurobiology of drug abuse and addiction_NIDA
Neurobiology of drug abuse and addiction_NIDA
 
Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...
Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...
Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...
 
David Borsook, "Opioids for Chronic Pain: Where is the Science for the Clinic...
David Borsook, "Opioids for Chronic Pain: Where is the Science for the Clinic...David Borsook, "Opioids for Chronic Pain: Where is the Science for the Clinic...
David Borsook, "Opioids for Chronic Pain: Where is the Science for the Clinic...
 
Rx15 general wed_800_revised4-6_volkow rx drug summit 2015 final ndv3
Rx15 general wed_800_revised4-6_volkow rx drug summit 2015 final ndv3Rx15 general wed_800_revised4-6_volkow rx drug summit 2015 final ndv3
Rx15 general wed_800_revised4-6_volkow rx drug summit 2015 final ndv3
 
Rx15 vision wed_200_ondcp_1_labelle_2jones_3spitznas
Rx15 vision wed_200_ondcp_1_labelle_2jones_3spitznasRx15 vision wed_200_ondcp_1_labelle_2jones_3spitznas
Rx15 vision wed_200_ondcp_1_labelle_2jones_3spitznas
 
National Summit On Opioid Safety
National Summit On Opioid  SafetyNational Summit On Opioid  Safety
National Summit On Opioid Safety
 
12Week IV, Discussion Post Care for the Client with a Subst
12Week IV, Discussion Post Care for the Client with a Subst12Week IV, Discussion Post Care for the Client with a Subst
12Week IV, Discussion Post Care for the Client with a Subst
 
12Week IV, Discussion Post Care for the Client with a Subst
12Week IV, Discussion Post Care for the Client with a Subst12Week IV, Discussion Post Care for the Client with a Subst
12Week IV, Discussion Post Care for the Client with a Subst
 
12Week IV, Discussion Post Care for the Client with a Subst.docx
12Week IV, Discussion Post Care for the Client with a Subst.docx12Week IV, Discussion Post Care for the Client with a Subst.docx
12Week IV, Discussion Post Care for the Client with a Subst.docx
 
12Week IV, Discussion Post Care for the Client with a Subst.docx
12Week IV, Discussion Post Care for the Client with a Subst.docx12Week IV, Discussion Post Care for the Client with a Subst.docx
12Week IV, Discussion Post Care for the Client with a Subst.docx
 
Rx16 vs ukhealthcare_800_group
Rx16 vs ukhealthcare_800_groupRx16 vs ukhealthcare_800_group
Rx16 vs ukhealthcare_800_group
 
আসক্তি মুক্তি Ashokti mukti
আসক্তি মুক্তি Ashokti muktiআসক্তি মুক্তি Ashokti mukti
আসক্তি মুক্তি Ashokti mukti
 
Rx15 pharma wed_430_1_green_2yamada-dole
Rx15 pharma wed_430_1_green_2yamada-doleRx15 pharma wed_430_1_green_2yamada-dole
Rx15 pharma wed_430_1_green_2yamada-dole
 
Lowe-2014
Lowe-2014Lowe-2014
Lowe-2014
 
Managing Patients on Opioids for Chronic Noncancer Pain
Managing Patients on Opioids for Chronic Noncancer PainManaging Patients on Opioids for Chronic Noncancer Pain
Managing Patients on Opioids for Chronic Noncancer Pain
 
Neonatal Abstinence Syndrome - Tennessee's Epidemic and The State's Response
Neonatal Abstinence Syndrome - Tennessee's Epidemic and The State's ResponseNeonatal Abstinence Syndrome - Tennessee's Epidemic and The State's Response
Neonatal Abstinence Syndrome - Tennessee's Epidemic and The State's Response
 

Más de OPUNITE

Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynoteOPUNITE
 
Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynoteOPUNITE
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynoteOPUNITE
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_finalOPUNITE
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerOPUNITE
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingOPUNITE
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliOPUNITE
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyOPUNITE
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenOPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingOPUNITE
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesOPUNITE
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessOPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingOPUNITE
 
Rx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceRx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceOPUNITE
 
Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleOPUNITE
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattOPUNITE
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanOPUNITE
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerOPUNITE
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_groupOPUNITE
 
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldRx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldOPUNITE
 

Más de OPUNITE (20)

Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynote
 
Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynote
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynote
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_final
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelli
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsen
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategies
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceRx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2price
 
Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earle
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblatt
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_miller
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_group
 
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldRx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
 

Último

Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Varanasi Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Bangalore Call Girls Nelamangala Number 7001035870 Meetin With Bangalore Esc...
Bangalore Call Girls Nelamangala Number 7001035870  Meetin With Bangalore Esc...Bangalore Call Girls Nelamangala Number 7001035870  Meetin With Bangalore Esc...
Bangalore Call Girls Nelamangala Number 7001035870 Meetin With Bangalore Esc...narwatsonia7
 
Call Girls Dehradun Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Dehradun Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Dehradun Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Dehradun Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...chandars293
 
High Profile Call Girls Coimbatore Saanvi☎️ 8250192130 Independent Escort Se...
High Profile Call Girls Coimbatore Saanvi☎️  8250192130 Independent Escort Se...High Profile Call Girls Coimbatore Saanvi☎️  8250192130 Independent Escort Se...
High Profile Call Girls Coimbatore Saanvi☎️ 8250192130 Independent Escort Se...narwatsonia7
 
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...aartirawatdelhi
 
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...hotbabesbook
 
Vip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls Available
Vip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls AvailableVip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls Available
Vip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls AvailableNehru place Escorts
 
Call Girls Siliguri Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Siliguri Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Siliguri Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Siliguri Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls JaipurCall Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipurparulsinha
 
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore EscortsCall Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escortsvidya singh
 
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...Taniya Sharma
 
Call Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Lucknow Call girls - 8800925952 - 24x7 service with hotel room
Lucknow Call girls - 8800925952 - 24x7 service with hotel roomLucknow Call girls - 8800925952 - 24x7 service with hotel room
Lucknow Call girls - 8800925952 - 24x7 service with hotel roomdiscovermytutordmt
 
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Chandrapur Call girls 8617370543 Provides all area service COD available
Chandrapur Call girls 8617370543 Provides all area service COD availableChandrapur Call girls 8617370543 Provides all area service COD available
Chandrapur Call girls 8617370543 Provides all area service COD availableDipal Arora
 
Call Girls Jabalpur Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Jabalpur Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Jabalpur Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Jabalpur Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Bareilly Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Bareilly Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Bareilly Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Bareilly Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...Dipal Arora
 

Último (20)

Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Varanasi Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service Available
 
Bangalore Call Girls Nelamangala Number 7001035870 Meetin With Bangalore Esc...
Bangalore Call Girls Nelamangala Number 7001035870  Meetin With Bangalore Esc...Bangalore Call Girls Nelamangala Number 7001035870  Meetin With Bangalore Esc...
Bangalore Call Girls Nelamangala Number 7001035870 Meetin With Bangalore Esc...
 
Call Girls Dehradun Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Dehradun Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Dehradun Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Dehradun Just Call 9907093804 Top Class Call Girl Service Available
 
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 6297143586 𖠋 Will You Mis...
 
High Profile Call Girls Coimbatore Saanvi☎️ 8250192130 Independent Escort Se...
High Profile Call Girls Coimbatore Saanvi☎️  8250192130 Independent Escort Se...High Profile Call Girls Coimbatore Saanvi☎️  8250192130 Independent Escort Se...
High Profile Call Girls Coimbatore Saanvi☎️ 8250192130 Independent Escort Se...
 
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
 
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
 
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
 
Vip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls Available
Vip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls AvailableVip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls Available
Vip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls Available
 
Call Girls Siliguri Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Siliguri Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Siliguri Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Siliguri Just Call 9907093804 Top Class Call Girl Service Available
 
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls JaipurCall Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
 
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore EscortsCall Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
 
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...
 
Call Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service Available
 
Lucknow Call girls - 8800925952 - 24x7 service with hotel room
Lucknow Call girls - 8800925952 - 24x7 service with hotel roomLucknow Call girls - 8800925952 - 24x7 service with hotel room
Lucknow Call girls - 8800925952 - 24x7 service with hotel room
 
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
 
Chandrapur Call girls 8617370543 Provides all area service COD available
Chandrapur Call girls 8617370543 Provides all area service COD availableChandrapur Call girls 8617370543 Provides all area service COD available
Chandrapur Call girls 8617370543 Provides all area service COD available
 
Call Girls Jabalpur Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Jabalpur Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Jabalpur Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Jabalpur Just Call 9907093804 Top Class Call Girl Service Available
 
Call Girls Bareilly Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Bareilly Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Bareilly Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Bareilly Just Call 9907093804 Top Class Call Girl Service Available
 
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
 

Realities of addiction_volkow-final

  • 1. Reali&es  of  Addic&on   Dr.  Nora  Volkow   April  2  –  4,  2013   Omni  Orlando  Resort     at  ChampionsGate  
  • 2. Learning  Objec&ves   1.  Iden=fy  recent  increasing  trends  in  the  misuse   and  abuse  of  prescrip=on  drugs.   2.  Describe  the  ways  in  which  the  most   commonly  abused  prescrip=on  drug  classes   affect  the  brain  and  body.   3.  Explain  strategies  being  developed  and   implemented  that  will  increase  awareness  of   the  growing  problem  of  addic=on.  
  • 3. Disclosure  Statement   •  Dr.  Nora  Volkow  has  no  financial  rela=onships   with  proprietary  en==es  that  produce  health   care  goods  and  services.  
  • 4. Nora D. Volkow, M.D. Director
  • 5. Numbers in Millions  Prescrip&on  Drug  Misuse/Abuse  is  a  Major  Problem  in  the  US   Current  Drug  Use  Rates  in  Persons  Ages  12+   Source:    SAMHSA,  2011  Na2onal  Survey  on  Drug  Use  and  Health`  
  • 6. Prevalence of Past Year Drug Use Among 12th graders 2012 Monitoring the Future Study * Nonmedical use Drug   Prev.   Drug   Prev.   Tranquilizers*       5.3   Marijuana/Hashish   36.4   Hallucinogens   4.8   Small  Cigars   19.9   Seda&ves*     4.5   Hookah   18.3   Salvia     4.4   Synthe=c  Marijuana   11.3   OxyCon&n*     4.3   Snus   7.9   Hall  other  than  LSD   4.0   Narco2cs  o/t   Heroin*   7.9   MDMA  (Ecstasy)     3.8   Amphetamines*   7.9   Inhalants     2.9   Adderall*     7.6   Cocaine  (any  form)     2.7   Vicodin*   7.5   Ritalin*     2.6   Cough  Medicine*     5.6   LSD   2.4   Categories not mutually exclusive
  • 7. 0 100 200 300 400 500 600 700 800 900 1000 1100 0 1 2 3 4 5 hr Time After Amphetamine %ofBasalRelease AMPHETAMINE 0 50 100 150 200 0 60 120 180 Time (min) %ofBasalRelease Empty Box Feeding Di Chiara et al. FOOD VTA/SN nucleus accumbens frontal cortex These prescription drugs, like other drugs of abuse (cocaine, heroin, marijuana) raise brain dopamine levels Dopamine Neurotransmission Why Do People Abuse Prescription Drugs?
  • 8. Opioids: Examples: OxyContin, Vicodin Attach to opioid receptors in the brain and spinal cord, blocking the transmission of pain messages and causing an increase in the activity of dopamine How They Work… •  Postsurgical pain relief •  Management of acute or chronic pain •  Relief of coughs and diarrhea Opioids are Generally Prescribed for: Amydala (reward) NAc (reward) Thalamus (pain)
  • 9. Similari&es  Between  Illicit  and  Prescrip&on  Drugs  
  • 10. Stimulants Enhance brain activity by increasing the activity of brain excitatory chemical messengers, such as norepinephrine and dopamine, leading to mental stimulation Example: Ritalin How They Work… •  ADHD •  Narcolepsy •  Depression that does not respond to other treatments •  Asthma that does not respond to other treatment Stimulants Are Generally Prescribed For:
  • 12. •  Expectation of Drug Effects Expectation of clinical benefits vs euphoria high •  Context of Administration School, clinic, home vs bar, discotheque •  Dose and Frequency of Dosing Lower, fixed regimes vs higher, escalating use •  Route of Administration Oral vs injection, smoking, snorting What is the Difference Between Therapeutic Use and Abuse?
  • 13. "High"   "High"   0 20 40 60 80 100 0 20 40 60 80 100 0 10 20 30 40 50 60 70 80 %Peak [11C]Cocaine Time (min) [11C]Methylphenidate 0 10 20 30 40 50 60 70 80 Rewarding Effects Depend on How Fast the Drug Gets into the Brain
  • 14. 0 0.01 0.02 0.03 0.04 0.05 0.06 0 20 40 60 80 100 120 UptakeinStriatum(%/cc) Time (minutes) 0 0.01 0.02 0.03 0.04 0.05 0.06 UptakeinStriatum(%/cc) 0 0.0005 0.001 0.0015 0.002 0.0025 0.003 0.0035 0 20 40 60 80 100 120 UptakeinStriatum(nCi/cc) Time (minutes) iv cocaine iv Ritalin oral Ritalin Rate of Drug Uptake Into the Brain Cocaine (iv) and Ritalin (iv) produce a high but Ritalin (oral) does not. The slow brain uptake of oral Ritalin permits effective treatment without a high. 0 20 40 60 80 100 120 Time (minutes) Fast!!!Fast!!! Slow!!!
  • 15. Source:  Volkow,  ND  et  al.,  Journal  of  Neuroscience,  23,  pp.  11461-­‐11468,  December  2003.   Glucose  Metabolism  Was  Greatly  Increased   By  the  Expecta2on  of  the  Drug       Unexpected MP70 0 µmol/100g/min Expected MP Increases  in  Metabolism  Were  About  50%   Larger  When  MP  Was  Expected  Than   Unexpected   0 5 10 15 20 25 30 %Change Unexpected   MP   Expected   MP   Expected  MP   Got  Placebo  
  • 16. What  Has  Raised  Our  AUen2on  to  the     Problem  of  Prescrip2on  Drug  Abuse?    
  • 17. Source: SAMHSA Treatment Episode Data Set (TEDS), 2000-2010 28,326 37,649 45,882 52,664 60,824 71,048 82,359 98,386 122,185 142,124 157,171 0 20,000 40,000 60,000 80,000 100,000 120,000 140,000 160,000 180,000 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 More Than 5-Fold Increase In Treatment Admissions For Prescription Painkillers In the Past Decade 12   10   8   6   4   2   0   1990          1992          1994          1996          1998        2000          2002          2004          2006          2008   *Deaths  are  those  for  which  poisoning  by  drugs  (illicit,  prescrip=on,  and    over-­‐the-­‐counter)  was  the  underlying  cause. Drug  Overdose  Death  Rates    in  the  US  Have  More     Than  Tripled  since  1990   Na&onal  Vital  Sta&s&cs  System.       Drug    Overdose  Death  Rates  by  State  2008.   100  people  die  from  drug   overdoses  every  day  in  the  US  
  • 18. 35,00 0 30,00 0 25,00 0 20,00 0 15,00 0 10,00 0 5,000 0 Number  of  ED  Visits   9,000 6,000 3,000 0 Aged  5  to  11   Aged  12  to  17   Aged  18  to  25   Aged  26  to  34   Aged  35  or  Older   2005   2010   3,322   3,791   2,702   3,461   2,131   8,148   1,754   6,094   2,519   7,957   Number  of  ED  Visits   2005                                          2006                                        2007                                        2008                                          2009                                          2010   4,315   6,332   11,390   11,448   12,208   14,068   17,174   14,503   12,287   14,979   10,614   9,059   13,379   16,948   26,369   23,735   26,711   31,244   All   Males   Females   Emergency Department (ED) Visits Related to Stimulant Medications Source:  SAMHSA  Dawn  Report:Emergency  Department  Visits  Involving  AUen2on  Deficit/   Hyperac2vity  Disorder  S2mulant  Medica2ons  ,  January  24,  2013.    
  • 19. Data in Several States Show That Hepatitis C Virus Among Adolescents and Young Adults Has Increased in Recent Years Of  cases  with  available  risk  data,  injec2on  drug  use   (IDU)  was  the  most  common  risk  factor  for  HCV   transmission     Although  only  a  small  number  of  these   cases  responded  to  further  inves2ga2on…..   •     92%  reported  opioid        analgesic  abuse     •     89%  reported  heroin  use   •     95%  used  opioid  analgesics          before  switching  to  heroin   •     During  the  preceding  6  months,          the  most  frequently  injected          drugs  were  heroin  (50%)        and  opioid  analgesics  (30%)   CDC, MMWR, May 6, 2011/60(17); 537-541;CDC,  MMWR,  October  28,  2011/60(42):1457-­‐1458  
  • 20. Number of Opioid Prescriptions Dispensed by U.S. Retail Pharmacies, Years 1991-2011 76 78 80 86 91 96 100 109 120 131 139 144 151 158 169 180 192 201 202 210 219 0 50 100 150 200 250 91 92 93 94 95 96 97 98 99 2000 01 02 03 04 05 06 07 08 09 10 11 Prescriptions(millions) IMS’s Source Prescription Audit (SPA) & Vector One®: National (VONA) Opioids Hydrocodone Oxycodone
  • 21. Oxycodone and Hydrocodone Prescriptions 1998-2012 Codeine & Comb NON-INJ (USC 02232), Morphine & Opium NON-INJ (USC 0222), Morphine & Opium INJ (USC 02221), Codeine & Comb INJ (USC 02231). Source: SDI Health, VONA 16 19 22 25 27 29 31 34 38 43 47 49 54 57 57 72 83 90 96 101 106 110 120 126 132 133 130 131 136 134 0 20 40 60 80 100 120 140 160 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Millions Oxycodone (Schedule II) Hydrocodone (Schedule III)
  • 22. Opioid Prescriptions by Age 2 6 19 30 159 - 20 40 60 80 100 120 140 160 180 - 5 10 15 20 25 30 35 2002 2006 2009 2012 No.ofPrescriptions,Age40+(millions) No.ofPrescriptions(millions) 0 to 9 10 to 19 20 to 29 30 to 39 40+ IMS Health, Vector One® National Opioids Overdose Death by Age Group, US, 2008 Rate  per  100,000   Paulozzi LJ, J Safety Res 2012; 43(4): 283-289.
  • 23. 20%   15%   11%   10%   9%   27%   12%   11%   8%   5%   20%   16%   11%   9%   6%   20%   13%   9%   8%   7%   16%   12%   7%   6%   3%   0   0.1   0.2   0.3   Percentage of Prescriptions Dispensed for Opioid Analgesics from Outpatient US Retail Pharmacies, by Age Group 20062002 22%   16%   11%   10%   8%   27%   12%   11%   8%   5%   19%   18%   12%   8%   7%   24%   12%   10%   8%   7%   26%   17%   9%   7%   4%   0   0.2   0 to 9 10 to 19 20 to 29 30 to 39 ≥40 EN Phys Pediatrici an Dentist Emerg Med GP/FM/ DO Ortho Surg OB/GYN Intern Med Anesthes IMS Health, Vector One® National 23%   16%   13%   11%   6%   29%   12%   8%   8%   6%   17%   16%   13%   8%   8%   21%   10%   9%   8%   7%   25%   16%   7%   6%   6%   -­‐10%   10%   30%   2012
  • 24. Top Prescribers of Opioid Analgesics in 2012 0 10,000,000 20,000,000 30,000,000 40,000,000 50,000,000 60,000,000 20022003200420052006200720082009201020112012 Prescriptions GP/FM/DO Internal medicine Dentistry Orthopedic Surgery IMS Health, Vector One® National
  • 25. Percent   Source:  2010  Na2onal  Survey  on  Drug  Use  and  Health,  SAMHSA  2011.   Source  of  Prescrip&on  Drugs     (how  they  obtained  the  drugs  they  most  recently  used   nonmedically)   Rates  averaged  across  2009  and  2010  
  • 26. Jones, CM et al. JAMA, February 20, 2013; 309(7): 657-659. National Center for Health Statistics show drug overdose deaths increased for the 11th consecutive year in 2010 In  2010,  there  were  38,329  drug   overdose   deaths  in  the  United  States   Percentage  of  Overdose  Deaths  for    Specific  Psychotherapeu=c  and    CNS  Pharmaceu=cals  that  Involved  a  Single  Drug  Class,  US,  2010     Psychotherapeuticand CNSPharmaceuticals,% Opioid     Analgesics   (n=16,651)   An&epilep&c  &   An&parkinsonism   Drugs   (n=1,717)   Benzodizepines   (n=6,497)   Barbiturates   (n=296)   An&depressants   (n=3,889)   An&psycho&c  &   Neurolep&c   Drugs   (n=1,351)    Other   Psychotropic   Drugs   (n=24)   35 30 25 20 15 10 5 0
  • 27. Jones, CM et al. JAMA, February 20, 2013; 309(7): 657-659. PERCENT      Drug  Involvement  in  Pharmaceu=cal  Overdose  Deaths          Opioid  Analgesic  Involvement  in  Deaths  for  Specific  Drugs   Specific  Drug  Involvement  in  Pharmaceu&cal  Overdose   Deaths  USA,  2010   75.2 7.8 29.4 1.3 17.6 6.1 0.1 100 65.5 77.2 50 57.6 58 54.2 0 20 40 60 80 100 120
  • 28. How to Minimize the Diversion and Abuse of Prescription Medications Engage the Healthcare System
  • 29. Doctors Need to Know… What Opioid Prescriptions Have Been Given to Their Patients By Other Doctors or Practitioners This information should be: 1)  included in the patients’ electronic health care records 2)  accessible through a Prescription Drug Monitoring Program (PDMP) that provides immediate information and can cross-reference across States
  • 30. Mezei,  L  and  Murinson,  BB.,  J  Pain,  12,  1199  -­‐1208,  2011.   Education on Pain in Medical Schools Number of Hours of Pain Education Number  of    Schools   USA (median: 7 hours) Canada (median: 14 hours) Veterinarian schools: 75 hours on pain 0-5 5-10 10-15 15-20 20-25 25-30 >30
  • 31. •  Centers of Excellence in Pain Education (12 CoEPE) •  Consensus Workshop on Opioids for Chronic Pain ICs Involved: ORWH NIA OBSSR NINR NIDA NICHD NIDCR NIAMS NINDS NCCAM
  • 32. •  Efficacy of opioids for treating chronic pain •  How to administer opioids for optimal efficacy and minimal adverse effects •  Risks for addiction •  Populations differences •  What training is available (other than offered by industry) for teaching how and what type of opioids should be used in managing chronic pain? •  What research directions need to be pursued to determine best approaches for managing chronic pain with opioids? •  For research gaps, what are research priorities? Consensus Workshop: Opioids for Chronic Pain
  • 33. Prevention Strategies – Public Education CME Courses developed by NIDA & Medscape Education, funded by ONDCP Safe  Prescribing  for  Pain   Managing  Pain  Pa&ents     Who  Abuse  Rx  Drugs   Skills  and  tools  clinicians   can  use  to  screen  for  and   prevent  abuse  in  pa7ents   with  pain       Learn  symptoms  of  opioid  addic7on   and  dependence  in  pa7ents  with   chronic  pain,     and  how  to  screen  for,  prevent         and  treat  such  condi7ons    
  • 34. Pain  Medica&ons     •  Develop medications with slower abuse potential including drugs that don’t cross BBB (i.e., CBR2 agonist) •  Develop slow release formulations (low dose and long duration) •  Develop novel formulations to reduce abuse liability including mixture formulations (e.g., naloxone and buprenorphine) 0 0.0005 0.001 0.0015 0.002 0.0025 0.003 0.0035 0 20 40 60 80 100120 UptakeinStriatum(nCi/cc) Time (minutes) Slow!!!
  • 35. Prevention Strategies – Overdose Intervention •  Naloxone Distribution for opioid overdose victims. The potential for direct intervention to save lives. •  Naloxone Nasal Spray Development Needle-free, unit-dose, ready-to-use opioid overdose antidote NIDA  STTR  Grantee  –  An7Op,  Inc.,  Daniel  Wermeling,  CEO     Contact:  E-­‐mail:  dpwermeling@gmail.com,  Tel:   859-­‐221-­‐4138  
  • 36. Treatment of Addiction to Prescription Opioids Buprenorphine Currently  19,000  physicians   are  certified  to  prescribe  buprenorphine   (Source:  CSAT  Buprenorphine  Information  Center)   Targets the same opioid receptors as morphine (mu) but its much less potent, has a much longer half life and does not produce the same high as heroin or morphine
  • 37. Universal Drug Abuse Prevention May Reduce Prescription Drug Misuse Spoth et al., Addiction 2008;103(7):1160-1168. Spoth, et al., AJPM 2011;40(4):440-447 For 100 young adults in general population starting Rx abuse, only 35 young adults from an intervention community started. Overall, three studies now suggest the impact of universal prevention on prescription drug abuse.
  • 39. Numbers  in  Thousands   Source:  2011  Na2onal  Survey  on  Drug  Use  and  Health,  SAMHSA,  2012.   Large Number of Past Year Initiates of Pharmaceuticals: Persons Aged 12 or Older, 2011 Marijuana Pain Relievers Tranquilizers Ecstasy Inhalants Cocaine Stimulants LSD Heroin Sedatives PCP
  • 40. Overdoses of prescription painkillers have more than tripled in the past 20 years, killing more than 15,500 people in the US in 2009 For  every            overdose  death   from  prescrip=on  painkillers     there  are   treatment  admissions  for  abuse   emergency    department  visits   for  misuse  or  abuse   people  who  abuse   or  are  dependent   people  who  take  prescrip=on    painkillers  for  non-­‐medical  use   10   32   130   825